Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

[Pediatric and adolescent rheumatology-A rapidly developing field in pediatrics : Current status of juvenile idiopathic arthritis and juvenile dermatomyositis].

Huppertz HI, Minden K.

Z Rheumatol. 2019 Sep;78(7):585-586. doi: 10.1007/s00393-019-0675-y. German. No abstract available.

PMID:
31482211
2.

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results.

Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, Rabinovich CE, Kingsbury DJ, Marzan K, Chalom E, Horneff G, Kuester RM, Dare JA, Trachana M, Jung LK, Olson J, Minden K, Quartier P, Bereswill M, Kalabic J, Kupper H, Lovell DJ, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24044. [Epub ahead of print]

PMID:
31421019
3.

Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.

Drechsel P, Stüdemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, Spähtling-Mestekemper S, Aries P, Zink A, Klotsche J, Minden K.

Rheumatology (Oxford). 2019 Aug 14. pii: kez309. doi: 10.1093/rheumatology/kez309. [Epub ahead of print]

PMID:
31412128
4.

Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.

Burtchell J, Fetty K, Miller K, Minden K, Kantor D.

Neurol Ther. 2019 Jul 4. doi: 10.1007/s40120-019-0141-4. [Epub ahead of print]

PMID:
31273563
5.

Regulation of Fatty Acid Oxidation by Twist 1 in the Metabolic Adaptation of T Helper Lymphocytes to Chronic Inflammation.

Hradilkova K, Maschmeyer P, Westendorf K, Schliemann H, Husak O, von Stuckrad ASL, Kallinich T, Minden K, Durek P, Grün JR, Chang HD, Radbruch A.

Arthritis Rheumatol. 2019 May 27. doi: 10.1002/art.40939. [Epub ahead of print]

PMID:
31131995
6.

Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.

Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

J Rheumatol. 2019 Sep;46(9):1117-1126. doi: 10.3899/jrheum.180795. Epub 2019 Mar 1.

7.

Participation in school sports among children and adolescents with juvenile idiopathic arthritis in the German National Paediatric Rheumatologic Database, 2000-2015: results from a prospective observational cohort study.

Milatz F, Klotsche J, Niewerth M, Geisemeyer N, Trauzeddel R, Weißbarth-Riedel E, Kallinich T, Peitz J, Hartmann M, Minden K.

Pediatr Rheumatol Online J. 2019 Feb 11;17(1):6. doi: 10.1186/s12969-019-0306-9.

8.

The European network for care of children with paediatric rheumatic diseases: care across borders.

Dolezalova P, Anton J, Avcin T, Beresford MW, Brogan PA, Constantin T, Egert Y, Foeldvari I, Foster HE, Hentgen V, Kone-Paut I, Kuemmerle-Deschner JB, Lahdenne P, Magnusson B, Martini A, McCann L, Minden K, Ozen S, Schoemaker C, Quartier P, Ravelli A, Rumba-Rozenfelde I, Ruperto N, Vastert S, Wouters C, Zulian F, Wulffraat NM.

Rheumatology (Oxford). 2019 Jul 1;58(7):1188-1195. doi: 10.1093/rheumatology/key439.

PMID:
30668879
9.

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, Foeldvari I, Föll D, Frosch M, Ganser G, Gaubitz M, Günther A, Heinz C, Horneff G, Huemer C, Kopp I, Lommatzsch C, Lutz T, Michels H, Neß T, Neudorf U, Pleyer U, Schneider M, Schulze-Koops H, Thurau S, Zierhut M, Lehmann HW.

Semin Arthritis Rheum. 2019 Aug;49(1):43-55. doi: 10.1016/j.semarthrit.2018.11.004. Epub 2018 Dec 4. Review.

10.

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K.

Rheumatology (Oxford). 2019 Jun 1;58(6):975-986. doi: 10.1093/rheumatology/key406.

11.

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.

Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.

Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.

12.

Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort.

Sengler C, Zink J, Klotsche J, Niewerth M, Liedmann I, Horneff G, Kessel C, Ganser G, Thon A, Haas JP, Hospach A, Weller-Heinemann F, Heiligenhaus A, Foell D, Zink A, Minden K.

Arthritis Res Ther. 2018 Dec 13;20(1):276. doi: 10.1186/s13075-018-1765-y.

13.

Motivational Interviewing as a tool to enhance access to mental health treatment in adolescents with chronic medical conditions and need for psychological support (COACH-MI): study protocol for a clusterrandomised controlled trial.

Reinauer C, Viermann R, Förtsch K, Linderskamp H, Warschburger P, Holl RW, Staab D, Minden K, Muche R, Domhardt M, Baumeister H, Meissner T; COACH consortium.

Trials. 2018 Nov 14;19(1):629. doi: 10.1186/s13063-018-2997-5.

14.

Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.

Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G.

Scand J Rheumatol. 2019 Mar;48(2):95-104. doi: 10.1080/03009742.2018.1488182. Epub 2018 Nov 9.

PMID:
30411654
15.

[New support services for the care of young patients with rheumatic diseases].

Schalm S, Niewerth M, Minden K.

Z Rheumatol. 2018 Oct;77(8):685-693. doi: 10.1007/s00393-018-0547-x. Review. German.

PMID:
30251111
16.

Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood.

Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, Foeldvari I, Haas JP, Klein A, Tatsis S, Tenbrock K, Zink A, Klotsche J.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):471-481. doi: 10.1002/acr.23709.

PMID:
30044538
17.

The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON).

Listing M, Mönkemöller K, Liedmann I, Niewerth M, Sengler C, Listing J, Foell D, Heiligenhaus A, Klein A, Horneff G, Ganser G, Haas JP, Klotsche J, Minden K.

Arthritis Res Ther. 2018 May 30;20(1):106. doi: 10.1186/s13075-018-1588-x.

18.

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.

Tappeiner C, Klotsche J, Sengler C, Niewerth M, Liedmann I, Walscheid K, Lavric M, Foell D, Minden K, Heiligenhaus A.

Arthritis Rheumatol. 2018 Oct;70(10):1685-1694. doi: 10.1002/art.40544. Epub 2018 Aug 21.

19.

The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Holzinger D, Foell D, Horneff G, Foeldvari I, Tzaribachev N, Tzaribachev C, Minden K, Kallinich T, Ganser G, Clara L, Haas JP, Hügle B, Huppertz HI, Weller F, Consolaro A, Bovis F, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):211-218. doi: 10.1007/s00296-018-3953-0. Epub 2018 Apr 7.

20.

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium, Thomson W, Kastner DL, Woo P, Ombrello MJ.

Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28.

21.

Identification of an Amino Acid Motif in HLA-DRβ1 That Distinguishes Uveitis in Patients With Juvenile Idiopathic Arthritis.

Haasnoot AJW, Schilham MW, Kamphuis S, Hissink Muller PCE, Heiligenhaus A, Foell D, Minden K, Ophoff RA, Radstake TRDJ, Den Hollander AI, Reinards THCM, Hiddingh S, Schalij-Delfos NE, Hoppenreijs EPAH, van Rossum MAJ, Wouters C, Saurenmann RK, van den Berg JM, Wulffraat NM; ICON-JIA Study Group, Ten Cate R, de Boer JH, Pulit SL, Kuiper JJW.

Arthritis Rheumatol. 2018 Jul;70(7):1155-1165. doi: 10.1002/art.40484. Epub 2018 May 29.

22.

Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.

Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penadés I, Antón J, Ávila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Paz Gastañaga ME, Rama ME, Wouters C, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally MMTM, Rubio-Pérez N, Solau Gervais E, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Rheumatol. 2018 Jul;70(7):1144-1154. doi: 10.1002/art.40466. Epub 2018 May 20.

23.

Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.

Klotsche J, Minden K, Niewerth M, Horneff G.

Ann Rheum Dis. 2018 Jul;77(7):996-1002. doi: 10.1136/annrheumdis-2017-211968. Epub 2018 Feb 16.

PMID:
29453217
24.

Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis.

Schenck S, Rosenbauer J, Niewerth M, Klotsche J, Minden K, Schwarz T, Foeldvari I, Horneff G, Weller-Heinemann F, Holl RW, Thon A.

J Pediatr. 2018 Jan;192:196-203. doi: 10.1016/j.jpeds.2017.07.050.

PMID:
29246341
25.

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.

Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.

Arthritis Res Ther. 2017 Nov 22;19(1):256. doi: 10.1186/s13075-017-1462-2.

26.

Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography.

Beck MC, Glimm AM, Ohrndorf S, Minden K, Trauzeddel R, Werner SG, Horneff G, Backhaus M, Burmester GR, Kallinich T, Girschick H, Klotsche J.

Arthritis Res Ther. 2017 Oct 17;19(1):233. doi: 10.1186/s13075-017-1440-8.

27.

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation.

Klein A, Just GW, Werner SG, Oommen PT, Minden K, Becker I, Langer HE, Klee D, Horneff G.

Arthritis Res Ther. 2017 Jun 30;19(1):147. doi: 10.1186/s13075-017-1355-4.

28.

Transitional care for rheumatic conditions in Europe: current clinical practice and available resources.

Clemente D, Leon L, Foster H, Carmona L, Minden K.

Pediatr Rheumatol Online J. 2017 Jun 9;15(1):49. doi: 10.1186/s12969-017-0179-8.

29.

Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis.

Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K.

Semin Arthritis Rheum. 2017 Oct;47(2):269-275. doi: 10.1016/j.semarthrit.2017.05.003. Epub 2017 May 12.

PMID:
28583690
30.

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2018 Jan;77(1):21-29. doi: 10.1136/annrheumdis-2016-210456. Epub 2017 May 15.

31.

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.

Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, Guzman J, Horneff G, Kearsley-Fleet L, Klein A, Klotsche J, Magnusson B, Minden K, Munro JE, Niewerth M, Nordal E, Ruperto N, Santos MJ, Schanberg LE, Thomson W, van Suijlekom-Smit L, Wulffraat N, Hyrich K.

Pediatr Rheumatol Online J. 2017 Apr 19;15(1):31. doi: 10.1186/s12969-017-0161-5.

32.

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC.

Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M.

RMD Open. 2017 Mar 21;3(1):e000366. doi: 10.1136/rmdopen-2016-000366. eCollection 2017.

33.

[Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].

Albrecht K, Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A.

Z Rheumatol. 2018 Mar;77(2):102-112. doi: 10.1007/s00393-017-0294-4. German.

PMID:
28324149
34.

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.

Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group, Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W.

Ann Rheum Dis. 2017 May;76(5):906-913. doi: 10.1136/annrheumdis-2016-210324. Epub 2016 Dec 7.

35.

Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course.

Kallinich T, Thorwarth A, von Stuckrad SL, Rösen-Wolff A, Luksch H, Hundsdoerfer P, Minden K, Krawitz P.

Pediatr Rheumatol Online J. 2016 Nov 24;14(1):63.

36.

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A.

Arthritis Res Ther. 2016 Nov 24;18(1):272.

37.

EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases.

Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S, Berggren K, van Pelt P, Wouters C, Waite-Jones J, Tattersall R, Wyllie R, Stones SR, Martini A, Constantin T, Schalm S, Fidanci B, Erer B, Demirkaya E, Ozen S, Carmona L.

Ann Rheum Dis. 2017 Apr;76(4):639-646. doi: 10.1136/annrheumdis-2016-210112. Epub 2016 Nov 1. Erratum in: Ann Rheum Dis. 2018 Jun;77(6):960.

38.

Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.

Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1113-1120. Epub 2016 Sep 8.

PMID:
27749226
39.

Systematic review and critical appraisal of transitional care programmes in rheumatology.

Clemente D, Leon L, Foster H, Minden K, Carmona L.

Semin Arthritis Rheum. 2016 Dec;46(3):372-379. doi: 10.1016/j.semarthrit.2016.06.003. Epub 2016 Jun 9. Review.

PMID:
27496195
40.

[Transition from pediatric to adult rheumatological care].

Minden K, Schalm S.

Z Rheumatol. 2016 Aug;75(6):635-45. doi: 10.1007/s00393-016-0140-0. Review. German.

PMID:
27444620
41.

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.

Klotsche J, Raab A, Niewerth M, Sengler C, Ganser G, Kallinich T, Niehues T, Hufnagel M, Thon A, Hospach T, Horneff G, Minden K.

Arthritis Rheumatol. 2016 Dec;68(12):3023-3034. doi: 10.1002/art.39796.

42.

[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"].

Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kötter I, Krüger K, Lakomek J, Lorenz HM, Manger B, Märker-Hermann E, Minden K, Müller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Rüther W, Schett G, Schuch F, Schulze-Koops H, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M.

Z Rheumatol. 2016 May;75(4):416-28. doi: 10.1007/s00393-016-0059-5. German.

PMID:
27138788
43.

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort.

Sengler C, Klotsche J, Niewerth M, Liedmann I, Föll D, Heiligenhaus A, Ganser G, Horneff G, Haas JP, Minden K.

RMD Open. 2015 Dec 8;1(1):e000074. doi: 10.1136/rmdopen-2015-000074. eCollection 2015.

44.

Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis:data from a cross-sectional analysis of a prospective nationwide study.

Tappeiner C, Klotsche J, Schenck S, Niewerth M, Minden K, Heiligenhaus A.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6):936-44. Epub 2015 Oct 30.

PMID:
26517055
45.

Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.

Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.

J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472. Epub 2015 Sep 15.

PMID:
26373564
46.

Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.

Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):46-54. doi: 10.1002/acr.22649.

47.

Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.

Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Job Deslandre C, Minden K, Punaro M, Block AJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2015 Oct;67(10):2759-70. doi: 10.1002/art.39234.

48.

Effect of untreated and treated temporomandibular joint arthritis on mandibular volume development in growing rabbits.

Präger TM, Rafayelyan S, Landau H, Pischon N, Minden K, Jost-Brinkmann PG, Müller-Hartwich R, Mußler A.

J Orofac Orthop. 2015 May;76(3):265-74. doi: 10.1007/s00056-015-0288-2.

PMID:
25929713
49.

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).

Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.

Ann Rheum Dis. 2016 May;75(5):855-61. doi: 10.1136/annrheumdis-annrheumdis-2014-206747. Epub 2015 Apr 29.

PMID:
25926155
50.

Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.

Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.

Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145.

Supplemental Content

Loading ...
Support Center